GSK PLC Sponsored ADR (NYSE:GSK) Receives $44.13 Consensus PT from Analysts

GSK PLC Sponsored ADR (NYSE:GSK) has been assigned a consensus rating of “Hold” from the seven ratings firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $44.1250.

A number of research firms have recently weighed in on GSK. Bank of America upgraded GSK from an “underperform” rating to a “neutral” rating in a research report on Tuesday, November 25th. Wall Street Zen raised GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, September 5th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of GSK in a research note on Wednesday. Cfra set a $53.00 price target on shares of GSK in a research note on Thursday, October 30th. Finally, Jefferies Financial Group restated a “buy” rating on shares of GSK in a report on Monday, October 27th.

GSK Trading Down 0.5%

GSK opened at $47.79 on Friday. GSK has a 1-year low of $31.72 and a 1-year high of $48.69. The stock has a market capitalization of $97.03 billion, a PE ratio of 13.50, a PEG ratio of 1.90 and a beta of 0.50. The company has a current ratio of 0.87, a quick ratio of 0.57 and a debt-to-equity ratio of 1.07. The firm has a 50-day moving average price of $44.97 and a two-hundred day moving average price of $41.17.

GSK (NYSE:GSK) last released its quarterly earnings results on Wednesday, October 29th. The pharmaceutical company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.26 by $0.22. GSK had a net margin of 17.16% and a return on equity of 51.07%. The business had revenue of $11.35 billion for the quarter, compared to analysts’ expectations of $8.21 billion. During the same period in the prior year, the firm earned $0.50 earnings per share. GSK’s revenue was up 6.7% compared to the same quarter last year. GSK has set its FY 2025 guidance at 4.730-4.810 EPS. As a group, equities analysts anticipate that GSK will post 4.14 earnings per share for the current fiscal year.

GSK Cuts Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, January 8th. Investors of record on Friday, November 14th will be paid a dividend of $0.4171 per share. The ex-dividend date of this dividend is Friday, November 14th. This represents a $1.67 dividend on an annualized basis and a dividend yield of 3.5%. GSK’s payout ratio is 46.05%.

Hedge Funds Weigh In On GSK

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vermillion & White Wealth Management Group LLC bought a new position in GSK in the 3rd quarter worth $111,000. Triumph Capital Management bought a new position in shares of GSK in the third quarter worth about $40,000. Verity Asset Management Inc. lifted its position in shares of GSK by 13.7% during the 3rd quarter. Verity Asset Management Inc. now owns 20,577 shares of the pharmaceutical company’s stock worth $888,000 after purchasing an additional 2,482 shares during the last quarter. 1248 Management LLC boosted its stake in GSK by 314.6% during the 3rd quarter. 1248 Management LLC now owns 1,053 shares of the pharmaceutical company’s stock valued at $46,000 after purchasing an additional 799 shares during the period. Finally, Horizon Investments LLC grew its holdings in GSK by 7.9% in the 3rd quarter. Horizon Investments LLC now owns 18,979 shares of the pharmaceutical company’s stock valued at $819,000 after buying an additional 1,387 shares during the last quarter. Institutional investors own 15.74% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.